T1	total-participants 392 395	152
T2	eligibility 396 499	patients with early-stage breast cancer scheduled to received adjuvant anthracycline-based chemotherapy
T3	intervention 24 58	guideline-based antiemetic therapy
T4	total-participants 973 976	152
T5	condition 62 89	nausea and vomiting control
T6	outcome 1181 1227	Complete control of acute and delayed vomiting
T7	outcome 1346 1390	complete control of acute and delayed nausea
